Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib

Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Botrus, Gehan, Roe, Denise, Jameson, Gayle S., Junior, Pedro Luiz Serrano Uson, Korn, Ronald Lee, Caldwell, Lana, Bargenquast, Taylor, Miller, Max, Borazanci, Erkut Hasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687686/
https://www.ncbi.nlm.nih.gov/pubmed/36359225
http://dx.doi.org/10.3390/biomedicines10112705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687686/
https://www.ncbi.nlm.nih.gov/pubmed/36359225
http://dx.doi.org/10.3390/biomedicines10112705

Ejemplares similares